NASDAQ · PIRS
Pieris Pharmaceuticals, Inc.
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
Loading market information…
NASDAQ · WENA · USD
Stock price
Quote as of Sep 16, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Anew Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Anew Medical, Inc. is a biopharmaceutical firm dedicated to developing innovative treatments for conditions affecting the brain and nervous system, age-related illnesses, and specialized diagnostic tools. Their pipeline includes advanced cell and gene therapies specifically designed to alleviate symptoms of aging-related conditions, such as dementia, Alzheimer's disease, and various neuromuscular disorders. Additionally, Anew Medical is engaged in developing biologics and biosimilars for cancer treatment, alongside research into therapies targeting melanocortin receptors. A key strategic alliance exists with Japan's Okinawa Research Center, focusing on the collaborative research and development of Klotho gene therapy. This initiative aims to extend human longevity and diminish the impact of age-related diseases. The company maintains its headquarters in Omaha, Nebraska.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
$1.12-$0.01 (-0.89%)
Reunion Neuroscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.8% below the high.
€0.21-€0.01 (-2.38%)
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.46% below the high.
$0.19-$0.00 (-1.53%)
Theriva Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.99% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
CA$9.00+CA$0.20 (+2.27%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.27% below the high.
$0.83+$0.00 (+0.35%)
Imunon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.61% below the high.
$0.03-$0.00 (-9.09%)
Nymox Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.99% below the high.
